Search
forLearn
5 / 7 resultslearn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Procyanidin
bioflavonoid found in plants with antioxidant and hair stimulating properties
Research
5 / 1000+ results
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
research Kisspeptin and LH Pulsatile Temporal Coupling in PCOS Patients
Women with regular menstrual cycles and PCOS have linked kisspeptin and LH hormone patterns, unlike those with irregular cycles.
Community Join
5 / 1000+ resultscommunity Kintor money grab, unacceptable
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Kintors 1% Pyrilutamide comes in October/November
Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.
community Kintor's email response to me, regarding false advertising, and my proposal for them to develop a topical dut formulation with meaningful efficacy.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
community Mildly Interesting: Kintor removes the annotation that pictures are from clinical experiments and that KX-826 gives "real" visible results, editing their Amazon page once again
Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.